- Previous Close
11.23 - Open
11.35 - Bid 10.98 x --
- Ask 11.08 x --
- Day's Range
10.42 - 11.89 - 52 Week Range
6.15 - 40.90 - Volume
1,340,000 - Avg. Volume
545,226 - Market Cap (intraday)
517.362M - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-0.79 - Earnings Date Nov 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 4, 2019
- 1y Target Est
29.00
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is headquartered in Bromma, Sweden.
www.mobergpharma.se9
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MOB.ST
View More
Performance Overview: MOB.ST
Trailing total returns as of 9/16/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MOB.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MOB.ST
View MoreValuation Measures
Market Cap
524.37M
Enterprise Value
202.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
103.39
Price/Book (mrq)
0.56
Enterprise Value/Revenue
41.06
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-2.43%
Return on Equity (ttm)
-3.13%
Revenue (ttm)
4.93M
Net Income Avi to Common (ttm)
-22.75M
Diluted EPS (ttm)
-0.79
Balance Sheet and Cash Flow
Total Cash (mrq)
325.96M
Total Debt/Equity (mrq)
0.43%
Levered Free Cash Flow (ttm)
-148.77M
Research Analysis: MOB.ST
View MoreCompany Insights: MOB.ST
MOB.ST does not have Company Insights